Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Patidistrogene bexoparvovec - Myonexus Therapeutics/Sarepta Therapeutics

Next Previous
X
Search
Drug Profile

Patidistrogene bexoparvovec - Myonexus Therapeutics/Sarepta Therapeutics

Alternative Names: MYO-102; scAAVrh74-tMCK-hSGCA; scAAVrh74.tMCK.hSGCA; SRP-9004

Latest Information Update: 28 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nationwide Children's Hospital
  • Developer Myonexus Therapeutics; Nationwide Children's Hospital
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sarcoglycanopathies
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Limb girdle muscular dystrophies

Most Recent Events

  • 28 Jan 2022 No recent reports of development identified for phase-I development in Limb-girdle-muscular-dystrophies in USA (IM)
  • 09 Jan 2020 MYO 102 is still in clinical trials for Limb girdle muscular dystrophies in USA (Sarepta pipeline, January 2020)
  • 02 Jan 2019 MYO 102 receives Orphan Drug status for Sarcoglycanopathies in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top